<?xml version="1.0" encoding="UTF-8"?>
<p class="p">In MLT, synthetic fatty acids are newly designed with the aim of regulating membrane microdomain distribution mimicking natural lipids [
 <xref rid="B204-ijms-20-02167" ref-type="bibr" class="xref">204</xref>]. Thus, MLT is a sophisticated therapeutic approach to make protein–protein interactions targetable in an environment where those interactions are not amenable to manipulation [
 <xref rid="B139-ijms-20-02167" ref-type="bibr" class="xref">139</xref>,
 <xref rid="B205-ijms-20-02167" ref-type="bibr" class="xref">205</xref>,
 <xref rid="B206-ijms-20-02167" ref-type="bibr" class="xref">206</xref>]. Many diseases are already being targeted by MLT. The most relevant fields in which MLT molecules are being developed are listed below and further reviewed in [
 <xref rid="B19-ijms-20-02167" ref-type="bibr" class="xref">19</xref>] (
 <xref ref-type="fig" rid="ijms-20-02167-f006" class="xref">Figure 6</xref>).
 <list list-type="bullet" class="list">
  <list-item class="list-item">
   <p class="p">Oncology. The basis of developing MLT in oncology comes from the finding that membrane lipid composition might work as a switch allowing or compromising propagation of proliferation signals received at the PM in tumor cells [
    <xref rid="B196-ijms-20-02167" ref-type="bibr" class="xref">196</xref>,
    <xref rid="B207-ijms-20-02167" ref-type="bibr" class="xref">207</xref>]. Many molecules have been developed since the discovery membrane-altering mechanism of action of doxorubicin [
    <xref rid="B199-ijms-20-02167" ref-type="bibr" class="xref">199</xref>]. One of the most promising molecules is rationally-designed 2-OHOA (2-hydroxyoleic acid) [
    <xref rid="B208-ijms-20-02167" ref-type="bibr" class="xref">208</xref>], which is currently being tested in clinical trials for the treatment of glioma. 2-OHOA activates SMS increasing its product, SM, and decreasing its substrate PtdEtn in membranes of cancer cells but not of healthy cells because of the higher levels of SM found in tumor cells [
    <xref rid="B138-ijms-20-02167" ref-type="bibr" class="xref">138</xref>]. 2OHOA was the first rationally designed MLT molecule to arrive clinical trials. It has shown good pharmaceutical efficacy and safety against cancer in humans (ClinicalTrials.gov identifier #NCT01792310). After a first-in-man phase I/IIA trial in patients with solid tumors, 43% glioma patients responded to treatment, although this percentage almost doubled (ca. 80%) if patients previously pretreated with avastin were disregarded [
    <xref rid="B6-ijms-20-02167" ref-type="bibr" class="xref">6</xref>]. Other molecules being explored in oncology follow here: 2-hydroxylinoleic acid is on phase II clinical trial. This PUFA binds to membrane and inhibits the Akt/mTORC1 axis and induces specific cancer cell autophagy [
    <xref rid="B209-ijms-20-02167" ref-type="bibr" class="xref">209</xref>]. Hydroxytriolein is a triacylglycerol mimetic synthetic lipid analogue of triolein shown to block cancer cell growth in vitro through the β-catenin pathway, downregulation of the MEK-ERK axis, and production of Reactive Oxygen Species and apoptosis [
    <xref rid="B210-ijms-20-02167" ref-type="bibr" class="xref">210</xref>]. Worth mentioning are propofol-docosahexaenoic acid (P-DHA) and its analogue edelfosine (reviewed in [
    <xref rid="B6-ijms-20-02167" ref-type="bibr" class="xref">6</xref>]). Examples of anticancer therapies based on inhibitors targeting enzyme regulators of lipid metabolism are orlistat (Roche Xenical
    <sup class="sup">®</sup>), a FASN inhibitor administered in the treatment of breast cancer [
    <xref rid="B211-ijms-20-02167" ref-type="bibr" class="xref">211</xref>]; and ABC294640, a sphingosine kinase 2 and dihydroceramide desaturase inhibitor currently under an Ib/II clinical trial (ClinicalTrials.gov identifier #NCT02757326).
   </p>
  </list-item>
  <list-item class="list-item">
   <p class="p">Metabolic and cardiovascular diseases: The use of dietary lipids for the treatment of diabetes or obesity is a clear case of MLT. For example, body weight reductions where achieved in rats with daily supplements of olive oil (made of 70%–80% oleic acid) but not with supplements of its trans analogue elaidic acid, due to the different structure of both FA [
    <xref rid="B44-ijms-20-02167" ref-type="bibr" class="xref">44</xref>,
    <xref rid="B212-ijms-20-02167" ref-type="bibr" class="xref">212</xref>]. Furthermore, oleic acid analogues induce reduction of body weight in rats by promoting overexpression of uncoupling proteins UCP1 and UCP3 and decreasing food intake [
    <xref rid="B212-ijms-20-02167" ref-type="bibr" class="xref">212</xref>]. A high intake of oleic acid has also been shown to improve glycemic status and reduce saturated FA levels of diabetic patients while increasing those of unsaturated FA [
    <xref rid="B159-ijms-20-02167" ref-type="bibr" class="xref">159</xref>]. In the case of cardiovascular conditions, high oleic acid intake and ω-3 FA consumption were linked to reduced blood pressure values [
    <xref rid="B213-ijms-20-02167" ref-type="bibr" class="xref">213</xref>,
    <xref rid="B214-ijms-20-02167" ref-type="bibr" class="xref">214</xref>]. This reduction is even greater with 2-hydroxioleic acid treatment [
    <xref rid="B215-ijms-20-02167" ref-type="bibr" class="xref">215</xref>,
    <xref rid="B216-ijms-20-02167" ref-type="bibr" class="xref">216</xref>]. Furthermore, unsaturated FA are cardioprotective [
    <xref rid="B217-ijms-20-02167" ref-type="bibr" class="xref">217</xref>].
   </p>
  </list-item>
  <list-item class="list-item">
   <p class="p">Neurodegenerative disorders: Behind adipose tissue, the central nervous system concentrates the largest depot of lipids in the body making it a primary target for MLT strategies. Alzheimer’s disease risk has been inversely associated with ω-3 polyunsaturated fatty acid (PUFA) consumption [
    <xref rid="B218-ijms-20-02167" ref-type="bibr" class="xref">218</xref>]. In detail, the altered amyloid precursor protein (APP) proteolysis upon DHA abundance was the basis to design 2-hydroxioleic-DHA (2-OHDHA). A four-month treatment with 2-OHDHA in a severe Alzheimer’s disease mice model (5XFAD) restored cognition to control values [
    <xref rid="B219-ijms-20-02167" ref-type="bibr" class="xref">219</xref>,
    <xref rid="B220-ijms-20-02167" ref-type="bibr" class="xref">220</xref>]. Spinal cord injury might also benefit from MLT approaches (reviewed in [
    <xref rid="B19-ijms-20-02167" ref-type="bibr" class="xref">19</xref>]). Albumin-oleic acid complex induces significant motor recovery (~ 40%) in rats with spinal cord injury (SCI) [
    <xref rid="B221-ijms-20-02167" ref-type="bibr" class="xref">221</xref>], ameliorating both spasticity and pain. The oleic acid analogue NFX88 (Neurofix) is undergoing clinical trials for the treatment of neuropathic pain in patients with SCI. Finally, a phase II/III clinical trial (ClinicalTrials.gov identifier #NCT00706147) is being developed to evaluate the efficacy of the lipid interacting hydroxylamine derivative arimoclomol in familial amyotrophic lateral sclerosis.
   </p>
  </list-item>
  <list-item class="list-item">
   <p class="p">Other conditions that are bound to be ameliorated using MLT include infectious diseases, chemotherapeutic neuropathy, wound healing, retinopathies, nephropathies, acetaminophen liver toxicity, sunburn, ischemia reperfusion, intracranial hemorrhage, atrial fibrillation, vascular hypertension damage, and myocardial infarction as reviewed in [
    <xref rid="B19-ijms-20-02167" ref-type="bibr" class="xref">19</xref>].
   </p>
  </list-item>
 </list>
</p>
